Benjamin Garmezy, MD

Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.

At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.

Discover key takeaways on tumor markers, the BEP vs. EP debate, and the role of surgery in stage II testicular cancer.

Oncology Decoded provides the current management of metastatic bladder cancer, recent advancements in systemic therapy, patient selection, and AE mitigation.

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

Manojkumar Bupathi, MD, MS; and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may affect genitourinary cancer care.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.

Experts weigh in on the practical applications of PSMA PET imaging

Manojkumar Bupathi, MD, MS; Benjamin Garmezy, MD; Mike Lattanzi, MD, and x Damian N. Sorce, MD discuss how the practical applications of PSMA PET imaging, risk stratification, and evolving treatment strategies for advanced prostate cancer.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

Panelists discuss how upcoming studies at ASCO 2025 could change practice in kidney, bladder, and prostate cancer, highlighting research on novel drug combinations, biomarkers, organ-sparing approaches, and AI-driven treatment selection.

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

Panelists discuss how the evolving landscape of adjuvant therapy in kidney cancer, including targeted therapies and immunotherapy like pembrolizumab, offers curative potential for high-risk patients, with a focus on risk stratification, treatment sequencing, and managing recurrence while weighing benefits and toxicities.

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.